NIH's New REACH Competition Bars Everyone Who Ever Won One. That Is the Whole Strategy.

Federal grant programs rarely tell you who is not allowed to win. RFA-OD-27-009 does, in a single sentence that reshapes the entire competition: previous recipients of NIH Centers for Accelerated Innovations and REACH awards are ineligible.

That one clause converts a national open competition into a deliberately redistributive one. To understand why it matters, you have to know who it removes.

The RFA — formally Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional) — was posted September 24, 2026 and closes November 10, 2026 at 5:00 PM local time, with an expiration date of November 11. It is administered by NIGMS on behalf of NIH, with all NIH Small Business Program institutes and centers participating. Earliest anticipated start is June 2027. No letter of intent is required. We covered the forecast of this program when it first appeared in June: Granted News.

The $5 million figure is a one-year number

Grants.gov lists total program funding of $5,000,000 and up to five awards. Taken at face value, that reads as $1 million per hub, one time — a modest technology-transfer pilot.

The full announcement tells a different story: $20,000,000 estimated for up to five awards, with a budget ceiling of $1,000,000 in total costs per year and a project period of up to four years.

Five hubs × $1 million per year × four years = $20 million. The $5 million on the opportunity listing is the first-year obligation, not the program. Anyone sizing institutional commitment against $1 million of total federal support is underestimating the award by a factor of four — and, more importantly, misreading the time horizon. This is a four-year operating commitment to stand up and run a commercialization engine, not a one-shot pilot grant.

Who is locked out

The ineligibility clause covers two generations of NIH proof-of-concept infrastructure.

The NCAI program, launched in 2013 by NHLBI with roughly $31.5 million across three multi-institutional consortia, funded the Boston Biomedical Innovation Center, the NIH Center for Accelerated Innovation at the Cleveland Clinic, and the University of California Center for Accelerated Innovation, the last of which drew $12 million across five UC medical campuses.

The 2015 REACH cohort — authorized, as this one is, under the Phase 0 Proof of Concept Partnership pilot authority in Section 5127 of the 2011 SBIR/STTR Reauthorization Act — funded three hubs at $1 million per year for four years: the Long Island Bioscience Hub at Stony Brook University, MN-REACH at the University of Minnesota, and ExCITE at the University of Louisville. Those three matched their NIH awards 1:1 with institutional and partner money.

The 2019 cohort added hubs including KYNETIC at the University of Kentucky and SPARK REACH at the CU Anschutz Medical Campus.

The 2023 cohort, announced October 19, 2023, funded five hubs spanning 76 non-profit research institutions across 12 states: CBC-HITES led by Northwestern University, UM-BILD at the University of Maryland Baltimore, SIHI-REACH at the University of Montana, a Gulf Coast Consortia hub led by Texas A&M Health, and the Mid-South REACH Hub led by Vanderbilt University.

Add it up and the barred list runs to roughly a dozen lead institutions, including several of the most commercialization-sophisticated academic medical enterprises in the country. Northwestern, Vanderbilt, Minnesota, Texas A&M, Maryland, the entire University of California system's accelerated-innovation apparatus, Cleveland Clinic, and the Boston consortium are all out as primary applicants.

This is the rare federal competition where the institutions with the deepest demonstrated track record in exactly the thing being funded cannot apply. For a mid-tier research university with a functioning tech-transfer office, that is the most favorable structural fact in any NIH competition this quarter.

The eligibility gate that actually screens people

Removing the incumbents does not make this an open call. The limiting language is precise:

"The primary applicant organization must be a university or other research institution that participates in the NIH STTR program. Participation means that a university or other research institution has been a formal partner to a small business on an STTR award."

That is a documentary requirement, not an aspiration. STTR, unlike SBIR, mandates that a research institution perform at least 30% of the work on the award. So the eligibility test is: has your institution ever been the named research partner on an NIH STTR grant?

Three consequences follow.

First, go check. This is a database question with a yes-or-no answer, and the answer is in NIH RePORTER and SBIR.gov award records. Many universities have STTR partnerships they are not centrally tracking, because the award flows to the small business and the institution receives a subaward. The office that knows is Sponsored Programs, not the tech-transfer office. If a single faculty member partnered with a startup on an NIH STTR Phase I in the last decade, the institution qualifies.

Second, the gate is low but not trivially low. It excludes institutions that have never done STTR work at all — which is a meaningful fraction of smaller research universities, primarily undergraduate institutions, and most standalone research institutes without a startup-facing culture. If your institution has SBIR relationships but has never been a formal STTR partner, you do not qualify on SBIR history alone.

Third, eligibility otherwise is broad. Public and private institutions of higher education, 501(c)(3) nonprofits, and non-501(c)(3) nonprofits may all apply. Businesses may not be the primary applicant. Foreign organizations and foreign components are excluded.

The match requirement got quieter, and that is a trap

The 2015 REACH hubs matched NIH dollars 1:1. The current RFA does something subtler. Grants.gov reports no cost-sharing requirement. The announcement itself says cost matching of $250,000 per year is encouraged, and then adds the line that matters:

"the amount will not impact the evaluation of the application."

So matching is not required, and the quantity of match is explicitly excluded from scoring. An institution reading quickly will conclude that match is optional theater and budget zero.

That conclusion is wrong, for a structural reason buried in the program design. Each hub must select and fund at least five Technology Development Projects annually, and federal support per project is capped at up to $100,000 in direct costs from the award, "supplemented by non-federal matching funds."

Run the hub budget. The ceiling is $1,000,000 in total costs per year — total, meaning inclusive of indirect. At a typical academic negotiated rate, the direct-cost pool is meaningfully smaller than $1 million. Five TDPs at $100,000 direct each consumes $500,000 of direct costs before the hub pays for a single staff position, and a hub is expected to run entrepreneurial training, commercialization mentoring, market-assessment services, and project management on what remains.

The arithmetic does not close without outside money. The $250,000 annual match is not scored as a number, but the three scored review criteria are Importance, Rigor and Feasibility, and Expertise and Resources — and a hub budget that cannot simultaneously fund five projects and operate the hub will fail on feasibility and resources regardless of what the cost-share instruction says. The match is unscored as a dollar figure and load-bearing as evidence of operability.

The right way to handle this in the application is to present committed non-federal resources as capacity, not as cost share: named industry partners with letters, a state economic development commitment, foundation or endowment funds, in-kind services from the medical center's regulatory and reimbursement staff. The reviewers are not scoring the dollar total. They are scoring whether the operating model works.

What the hub actually has to do

Eligible technologies must have advanced beyond basic discovery into early product development. The announcement names the categories: small-molecule therapeutics in lead optimization or preclinical stages; biologics and cell-based therapies; medical devices, whether interventional, diagnostic, or research tools; and health IT, software, and algorithms.

The hub's job is to provide seed funding, mentorship, market and regulatory assessment, prototype and feasibility support, and entrepreneurship training — and to push projects toward either a licensing deal or a new small business that can go on to win SBIR/STTR funding. Public-private partnership is an explicit expectation.

The scored criteria tell you what to lead with:

• Importance rewards a hub model that addresses an unmet regional need. This is the opening for institutions in states without a dense biotech corridor. A hub in a region where no commercialization infrastructure exists has a stronger Importance case than a technically superior hub in Boston or the Bay Area. Name the gap, size it, and show what currently happens to a promising discovery at your institution — which is usually that it stalls.
• Rigor and Feasibility is where the TDP pipeline lives. Reviewers will want to see a credible inventory of named, de-identified-if-necessary technologies that are ready now, plus a defensible selection process, milestone-based tranching, and a kill-decision rule. A hub that cannot show five fundable projects for year one has not demonstrated feasibility.
• Expertise and Resources is about the operator, not the scientist. The hub director's record of moving academic technology into companies matters more than publication count. Reviewers in commercialization programs read for people who have done deals.

Five weeks, and the clock is the real constraint

From the September 24 posting to the November 10 deadline is about seven weeks, and anyone starting now has roughly five. That is tight for an application that needs institutional sign-off, partner letters, a governance structure, and a technology pipeline.

The sequence that fits in five weeks:

1. Confirm STTR partner history this week. Everything else is wasted effort if the answer is no.
2. Confirm you are not on the barred list. If your institution led or was the primary applicant on an NCAI center or any prior REACH hub, you are out — and note that the bar attaches to the award recipient, so a partner institution inside someone else's 76-institution consortium should verify its own status carefully rather than assume either answer.
3. Build the year-one TDP slate before writing the narrative. The pipeline determines whether the rest of the application is credible.
4. Secure partner and match letters in parallel, not sequentially. Non-federal commitments take longer to obtain than any section of the proposal takes to write.

The program's design is unusually legible about its intent: NIH is spending $20 million to build commercialization capacity in places that do not have it, and it has removed the institutions that already do. Programs with that shape do not come around often, and this one runs on a four-year clock that will not reopen soon.